At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

"AHA 2024: Muvalaplin shows promising Phase II results for elevated serum lipoprotein (a)" was originally created and ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

Lp (a) is a genetically driven variant of low-density lipoprotein (LDL) cholesterol, that is known to be an independent risk ...

Low-density lipoprotein (LDL) cholesterol: We call LDL "bad" cholesterol. Below 100 milligrams per deciliter (mg/dl) is ...

The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a ...

Eli Lilly (LLY) and Company announced “positive” Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a), or Lp(a), a genetically ...

Dyslipidemia, a risk factor for cardiovascular disease, is an increased level of serum total cholesterol, low-density lipoprotein cholesterol and triglycerides, or a decreased serum high-density ...

Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...